Cytokinetics Files 8-K for Regulatory Disclosure
Ticker: CYTK · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Cytokinetics filed a routine 8-K for regulatory updates.
AI Summary
Cytokinetics, Incorporated filed an 8-K on June 5, 2024, to report on events that require disclosure under Regulation FD and to file financial statements and exhibits. The filing does not detail specific transactions or financial results but serves as a formal notification to the SEC regarding the company's reporting obligations.
Why It Matters
This filing indicates Cytokinetics is meeting its regulatory reporting requirements, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard regulatory filing and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- 0000950170-24-069098 (filing_id) — Accession Number
- June 05, 2024 (date) — Date of Report
- 350 Oyster Point Boulevard, South San Francisco, CA 94080 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Cytokinetics?
The primary purpose is to satisfy the filing obligation for Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 05, 2024.
What is Cytokinetics' principal executive office address?
Cytokinetics' principal executive office is located at 350 Oyster Point Boulevard, South San Francisco, California 94080.
What is Cytokinetics' IRS Employer Identification Number?
Cytokinetics' IRS Employer Identification Number is 94-3291317.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-06-05 10:02:17
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20240605.htm (8-K) — 36KB
- cytk-ex99_1.htm (EX-99.1) — 9KB
- 0000950170-24-069098.txt ( ) — 158KB
- cytk-20240605.xsd (EX-101.SCH) — 24KB
- cytk-20240605_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Cytokinetics, Incorporated (the "Company") is furnishing with this Current Report on Form 8-K as Exhibit 99.1 hereto a copy of statements made by our President & CEO, Robert I. Blum, on July 5, 2024 at the Jefferies Global Healthcare Conference concerning market speculations and rumors regarding the Company's strategic plans and decision-making process. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing under the Securities Exchange Act, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Statements Made at Jefferies Global Healthcare Conference . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: June 5, 2024 By: /s/ John O. Faurescu John O. Faurescu, Esq. Associate General Counsel & Secretary